Dergiler / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 9

Lower serum 25-hydroxyvitamin D level is associated with impaired myocardial performance and left ventricle hypertrophy in newly diagnosed hypertensive patients

Sayfa
744–752
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Multivariate linear regression analysis showed that serum 25 (OH) D was independently associated with MPI (β=-0.426, p<0.001), LVMI (β=-0.345, p=<0.001), and LDL (β=0.140, p<0.026).Conclusion: Lower serum 25 (OH) D levels are significantly associated with impaired myocardial performance and LVMI

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Vitamin D deficiency is an independent risk factor for cardiovascular mortality.
📊
Temel Bulgular & Veri:The relationship between vitamin D level and left ventricle (LV) myocardial performance index (MPI=Tei index), which incorporates both LV systolic function and diastolic function, was not investigated in previous studies.
💡
Sonuç & Katkı:Multivariate linear regression analysis showed that serum 25 (OH) D was independently associated with MPI (β=-0.426, p<0.001), LVMI (β=-0.345, p=<0.001), and LDL (β=0.140, p<0.026).Conclusion: Lower serum 25 (OH) D levels are significantly associated with impaired myocardial performance and LVMI
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Vitamin D deficiency is an independent risk factor for cardiovascular mortality. The relationship between vitamin D level and left ventricle (LV) myocardial performance index (MPI=Tei index), which incorporates both LV systolic function and diastolic function, was not investigated in previous studies. We hypothesized that vitamin D level may be associated with LV function and geometry. We aimed to investigate the association between serum 25-hydroxyvitamin D (25 [OH] D) levels and MPI and LV hypertrophy in hypertensive patients with newly diagnosed and preserved ejection fraction.Methods: We studied 151 sequential newly diagnosed hypertensive subjects who lived in the Çukurova region without known cardiovascular risk factors or overt heart disease (mean age: 62.8±10.4 years). Serum 25 (OH) D was measured using a direct competitive chemiluminescent immunoassay. The patients were divided into two groups according to serum 25 (OH) D level: vitamin D-non-deficient group (vitamin D≥ 20.00 ng/mL, n=53) and vitamin D-deficient group (vitamin D< 20.00 ng/mL, n=98). MPI was defined as the sum of isovolumic contraction and relaxation times divided by the ejection time. LV mass index (LVMI) was calculated by using the Devereux formula and body surface area.Results: MPI and LVMI values were lower and low-density lipoprotein (LDL) levels were higher in patients who were vitamin D-non-deficient than patients who were vitamin D-deficient (p<0.05 for all). Multivariate linear regression analysis showed that serum 25 (OH) D was independently associated with MPI (β=-0.426, p<0.001), LVMI (β=-0.345, p=<0.001), and LDL (β=0.140, p<0.026).Conclusion: Lower serum 25 (OH) D levels are significantly associated with impaired myocardial performance and LVMI

🔖

Bu Makaleye Atıf Yap

ŞEKER, T., GÜR, M., UÇAR, H., TÜRKOĞLU, C., BAYKAN, A. O., ÖZALTUN, B., HARBALIOĞLU, H., KALKAN, G. Y., KAYPAKLI, O., KULOĞLU, O., ŞEN, Ö., KOÇ, M., ÇAYLI, M. (2015). Lower serum 25-hydroxyvitamin D level is associated with impaired myocardial performance and left ventricle hypertrophy in newly diagnosed hypertensive patients. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 9, 744–752. https://ajindex.com/articles/364002

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction, American Heart Association Science Advisory and Coordinating Committee. Circulation 1997
  2. [CrossRef] 2. Goswami R, Gupta N, Goswami D, Marwaha RK, Tandon N, Kochupillai N. Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi. Am J Clin Nutr 2000
  3. Feneis JF, Arora RR. Role of vitamin D in blood pressure homeostasis. Am J Ther 2010
  4. [CrossRef] 4. Semba RD, Houston DK, Ferrucci L, Cappola AR, Sun K, Guralnik JM, et al. Low serum 25-hydroxyvitamin D concentrations are associated with greater all-cause mortality in older communitydwelling women. Nutr Res 2009
  5. [CrossRef] 5. Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 2011
  6. [CrossRef] 6. Holick MF. Vitamin D deficiency. N Engl J Med 2007
  7. [CrossRef] 7. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003
  8. [CrossRef] 8. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, et al. Synthesis of 1,25- dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 2002
  9. Green JJ, Robinson DA, Wilson GE, Simpson RU, Westfall MV. Calcitriol modulation of cardiac contractile performance via protein kinase. J Mol Cell Cardiol 2006
  10. [CrossRef] 10. Fernandes JM, Rivera IR, de Oliveira Romão B, Mendonça MA, Vasconcelos ML, Carvalho AC, et al: Doppler-derived myocardial performance index in patients with impaired left ventricular relaxation and preserved systolic function. Echocardiography 2009
  11. [CrossRef] 11. Alihanoğlu YI, Kaya Z, Arı H, Karaarslan S, Yıldız BS, Karanfil M, et al. Assessment of left ventricular systolic and diastolic function with conventional and tissue Doppler echocardiography imaging techniques in patients administered tyrosine kinase inhibitor. Turk Kardiyol Dern Arş 2012
  12. [CrossRef] 12. WHO Scientific Group on the Prevention and Management of osteoporosis. Prevention and management of osteoporosis: report of a WHO scientific group. Geneva, Switzerland: WHO, 2003. 13. Institute of Medicine. Di